【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Next-Generation Biologics Market
1.2 Why Should You Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Next-Generation Biologics
2.1 Brief History of Biological Drug Development
2.1.1 Limitations of Present-Generation Biologics
2.2 The Promise of Next-Generation Biologics
2.2.1 Defining Next-Generation Biologics
2.2.1.1 A Definition of Regenerative Medicine
2.2.1.2 Extending Half-Life: Pegylation and Other Novel Strategies
3. World Next-Generation Biologics Market: Outlook and Forecast 2015-2025
3.1 The Next-Generation Biologics Market 2014
3.1.1 Development of the Next-Generation Biologics Market 2008-2014
3.1.2 Rising Demand for Biological Therapies
3.1.3 Next-Generation Drugs as a Share of the Biologics Market 2014
3.1.4 Main Sectors of the Next-Generation Biologics Market: Antibodies and Regenerative Medicine Lead the Way
3.1.5 Leading Companies in the Next-Generation Biologics Market 2014
3.2 The Next-Generation Biologics Market 2015-2025
3.2.1 Growth Drivers for Biological Drug Revenues 2015-2025
3.2.2 The Next-Generation Biologics Market Forecast 2015-2025
3.2.3 Product Launches in All Sectors to Drive Market Growth 2015-2025
3.2.4 Next-Generation Biologics: Market Restraints 2015-2025
3.2.5 Rising Market Shares for Next-Generation Insulins 2015-2025
4. Leading National Submarkets for Next-Generation Biologics 2015-2025
4.1 Leading National Submarkets for Next-Generation Biologics 2014
4.1.1 National Submarket Forecasts 2015-2025
4.1.2 How Will National Submarket Shares Change to 2025?
4.2 Rising Disease Incidence in Important Markets 2015-2025
4.3 Approval of Next-Generation Biologics in Leading National Submarkets
4.4 The US Will be the Largest Submarket for Next-Generation Biologics 2015-2025
4.4.1 US Submarket Forecast 2015-2025
4.5 Next-Generation Biologics in Japan 2015-2025
4.5.1 National Expertise in Stem Cell Research
4.5.2 Japanese Submarket Forecast 2015-2025
4.6 Next-Generation Biologics in Leading EU Countries 2015-2025
4.6.1 Regenerative Medicine Development in the EU
4.6.2 Market Access for Next-Generation Biologics in the EU
4.6.3 Germany: Submarket Forecast 2015-2025
4.6.4 France: Submarket Forecast 2015-2025
4.6.5 UK: Submarket Forecast 2015-2025
4.6.6 Italy and Spain: Submarket Forecasts 2015-2025
4.7 Next-Generation Biologics in Emerging Markets 2015-2025
4.7.1 Next-Generation Biologics Development in Emerging Countries
4.7.2 Chinese Submarket Forecast 2015-2025
4.7.3 Indian Submarket Forecast 2015-2025
5. Next-Generation Antibodies Submarket Outlooks 2015-2025
5.1 Strategies for Improving Antibody Therapies
5.1.1 Antibody-Drug Conjugates: Targeted Cytotoxic Therapies
5.1.2 Engineering Antibodies for Improved Potency
5.1.3 Bispecific Antibodies
5.2 Next-Generation Antibody Therapy Submarket 2013-2014
5.3 Next-Generation Antibody Therapy Submarket 2015-2025
5.3.1 Strong Revenue Growth for Next-Generation Antibodies 2015-2025
5.3.2 Blockbuster Potential Will Drive Growth to 2025: Kadcyla, Adcetris and Cosentyx
5.3.3 Next-Generation Antibodies: Submarket Restraints 2015-2025
5.4 Antibody-Drug Conjugates (ADC) Submarket 2015-2025
5.4.1 Antibody-Drug Conjugates Submarket Forecast 2015-2025
5.4.1.1 Kadcyla and Adcetris: Revenue Forecast 2015-2025
5.4.2 What Will Drive Growth for ADCs to 2025?
5.4.3 A Long Pipeline of ADCs in Clinical Development
5.4.3.1 CMC544 (Pfizer): NHL Development Halted but Trials in ALL Continue
5.4.3.2 NKTR-102 (Nektar Therapeutics): Phase III for Metastatic Breast Cancer
5.4.3.3 CDX-011: Potential for Accelerated Approval in Breast Cancer
5.5 Engineered Antibodies Submarket 2015-2025
5.5.1 Engineered Antibodies Submarket Forecast 2015-2025
5.5.1.1 Gazyva Will Lead the Submarket in 2025
5.5.2 Portfolio Management to Drive Growth 2015-2025
5.5.3 Engineered Antibodies Pipeline 2015
5.5.3.1 Benralizumab (MedImmune/Kyowa Hakko Kirin)
5.6 Bispecific Antibodies Submarket 2015-2025
5.6.1 Bispecific Antibodies Submarket Forecast 2015-2025
5.6.2 Bispecific Antibodies: Submarket Drivers and Restraints 2015-2025
5.6.3 One New Approval and Two Phase II Bispecific Antibodies in 2015
5.6.3.1 Blincyto (Amgen): The Second Approved Bispecific Antibody
6. Antibody Fragments and Novel Antibody-Like Drugs: Commercial Potential 2015-2025
6.1 Next-Generation Antibody Fragments: Beyond Fab Fragments
6.1.1 Antibody-Like Proteins Mimic Antibody Therapies
6.1.2 There Are Advantages to Using Fragments and Novel Scaffolds
6.2 Antibody Fragment and ALP Submarket 2015-2025
6.2.1 Antibody Fragment and ALP Submarket Forecast 2015-2025
6.2.2 Pharma Is Investing Strongly in Antibody Fragments and ALPs
6.2.3 Limited Late-Stage R&D Pipeline to Restrain Growth to 2025
6.3 Outlook for Next-Generation Antibody Fragments 2015-2025
6.3.1 Next-Generation Antibody Fragment Submarket Forecast 2015-2025
6.3.2 One Platform Leads the Pipeline in 2015
6.3.2.1 Three Nanobodies in Development for Rheumatoid Arthritis
6.3.2.2 Caplacizumab (Ablynx): Targeting an Orphan Indication
6.4 The Antibody-Like Protein Submarket 2015-2025
6.4.1 Antibody-Like Protein Submarket Forecast 2015-2025
6.4.2 Four ALPs in Clinical Development in 2014
6.4.2.1 Abicipar Pegol (Allergan/Molecular Partners): Development of the Lead Clinical ALP Delayed
6.5 Will Next-Generation Immunotoxins Change the Market to 2025?
6.5.1 Challenges with First Generation Immunotoxins
6.5.2 Fusion Protein Conjugates: Pipeline 2014
6.5.2.1 Moxetumomab Pasudotox
6.5.3 Humanised Immunotoxins
6.5.3.1 Using Granzyme B in Immunotoxins
6.5.3.2 Immunornases: A Future Development Opportunity for Immunotoxins
7. Next-Generation Insulin Submarket: Outlook 2015-2025
7.1 Strategies for Next-Generation Insulin Development
7.1.1 Reformulating Insulin for Convenient Administration
7.1.1.1 Oral Insulin
7.1.1.2 Inhaled Insulin
7.1.1.3 Exubera: A Failed Attempt at Reformulated Insulin
7.2 Next-Generation Insulin Submarket 2012-2014
7.2.1 Tresiba: Approved in the EU and Japan
7.2.1.1 Tresiba: Revenue Forecast 2015-2025
7.3 Next-Generation Insulin Submarket 2015-2025
7.3.1 Next-Generation Insulin Submarket Forecast 2015-2025
7.3.2 Product Launches in the US and EU Will Drive Submarket Growth 2015-2025
7.3.3 Next-Generation Insulin Submarket Restraints 2015-2025
7.3.3.1 Biosimilar Insulins Will be Available from 2015
7.4 Oral Insulin Submarket 2015-2025
7.4.1 Oral Insulin Submarket Forecast 2015-2025
7.4.2 Oral Insulin: Submarket Drivers and Restraints 2015-2025
7.4.3 A Limited Clinical-Stage Pipeline for Oral Insulin 2014
7.4.3.1 Oramed Pharmaceuticals: Oral Insulin in Phase II
7.4.3.2 Oshadi Icp: Phase II Currently Recruiting
7.4.3.3 IN-105: Biocon Partners with Bristol-Myers Squibb for Development
7.4.3.4 Diabetology: Multiple Deals Signed for Emerging Markets
7.4.3.5 Novo Nordisk: NN-1953
7.5 Ultra-Rapid Acting Insulin Submarket 2015-2025
7.5.1 Ultra-Rapid Acting Insulin Submarket Forecast 2015-2025
7.5.1.1 Will Inhaled Insulins Drive Revenue Growth to 2025?
7.5.2 Other Submarket Drivers and Restraints 2015-2025
7.5.3 Ultra-Rapid Acting Insulin Pipeline 2014
7.5.3.1 FIAsp (Novo Nordisk)
7.5.3.2 Adocia: Eli Lilly Opts to Discontinue Partnership
7.5.3.3 Halozyme Therapeutics
7.5.3.4 Biodel: Multiple Ultra Rapid Acting Candidates
7.5.3.5 Afrezza: Inhaled Insulin Nearing the Market
7.5.3.6 Adagio: A Second-Generation Inhaled Insulin
7.6 Ultra-Long Acting Insulin Submarket 2015-2025
7.6.1 Ultra-Long Acting Insulin Submarket Forecast 2015-2025
7.6.2 Revenue Growth Driven by Uptake of Tresiba
7.6.3 Ultra-Long Acting Insulin Pipeline 2015
7.6.3.1 Toujeo: Sanofi’s Next-Generation Insulin Analogue
7.6.3.2 LY2605541 (Eli Lilly)
7.6.3.3 FT-105 (Flamel Technologies)
7.6.3.4 LAPS-Insulin
8. Next-Generation Developments for Other Recombinant Proteins 2015-2025
8.1 Defining Next-Generation for Other Recombinant Protein Sectors
8.1.1 Next-Generation Interferon Beta: Plegridy Set for Approval in 2014
8.1.1.1 Plegridy: Revenue Forecast 2015-2025
8.1.1.2 Plegridy May Compete with Other Long-Acting Interferon Beta Therapies 2015-2025
8.1.2 Next-Generation G-CSF: Teva Expands its Filgrastim Franchise
8.1.2.1 Other Clinical-Stages Advances in Filgrastim Therapy 2014
8.2 Next-Generation Recombinant Coagulation Factors 2015-2025
8.2.1 Next-Generation Recombinant Coagulation Factors Submarket Forecast 2015-2025
8.2.2 Submarket Drivers and Restraints 2015-2025
8.2.3 Clinical Pipeline for Recombinant Coagulation Factors 2015-2025
8.2.3.1 Fused Factors: Biogen Idec’s Eloctate and Alprolix
8.2.3.2 Baxter’s BAX 855
8.2.3.3 CSL Behring’s rIX-FP: Albumin-Bound Coagulation Factors
8.2.3.4 Bayer’s BAY94-9027
8.2.3.5 Novo Nordisk’s N8-GP for Haemophilia A
8.2.3.6 Novo Nordisk’s N9-GP for Haemophilia B
8.2.4 Gene Therapy as a New Treatment Option for Haemophilia
8.3 Next-Generation Growth Hormones 2015-2025
8.3.1 Next-Generation Growth Hormone Submarket Forecast 2015-2025
8.3.2 Brand Loyalty Will Restrain Uptake of Next-Generation Hormones 2015-2025
8.3.3 Long-Acting Growth Hormones
8.3.3.1 Biopartners/LG Life Sciences: The First Long-Acting Growth Hormone
8.3.3.2 Prolor Biotech/OPKO Health
8.3.3.3 Novo Nordisk: Looking to Extend its Market-Leading Position
8.3.3.4 Versartis: XTEN Technology for Half-Life Extension
8.3.4 Reformulated Growth Hormones: Offering Convenient Dosing for Paediatric Patients
8.3.4.1 Critical Pharmaceuticals: Nasal Delivery of Somatropin
9. Regenerative Medicine: Commercial Outlook 2015-2025
9.1 The Regenerative Medicine Submarket 2012-2014
9.1.1 Defining Regenerative Medicine
9.2 The Regenerative Medicine Submarket: Revenue Projections 2015-2025
9.2.1 Stem Cell and Gene Therapy Launches to Drive Growth 2015-2025
9.3 The Stem Cell Therapies Submarket 2015-2025
9.3.1 Prochymal (Mesoblast) for GvHD
9.3.1.1 The Future for Prochymal: Approval in Crohn’s Disease?
9.3.1.2 A Note on Stem Cell Transplants
9.3.2 Stem Cell Therapies Submarket Forecast 2015-2025
9.3.3 Stem Cell Therapies: Submarket Drivers and Restraints 2015-2025
9.3.3.1 Will iPSCs Prove Effective for Stem Cell Therapy?
9.3.4 Stem Cell Therapies Late-Stage Pipeline 2015
9.3.4.1 Cx601 (TiGenix)
9.3.4.2 Mesoblast: Mesenchymal Stem Cell Therapies
9.3.4.3 Baxter Pharmaceuticals: A Leading Cardiovascular Candidate
9.3.4.4 StemEx (Gamida Cell)
9.4 Outlook for Tissue Engineering 2015-2025
9.4.1 Two Sectors Lead the Market: Wound and Cartilage Repair
9.4.1.1 Apligraf Leads the Wound Repair Submarket
9.4.1.2 Organogenesis Will Market Apligraf and Dermagraft from 2014
9.4.2 Tissue Engineering Submarket Forecast 2015-2025
9.4.3 Tissue Engineering: Submarket Drivers and Restraints 2015-2025
9.4.4 Future Developments in Cartilage Repair: Pipeline 2015
9.4.5 Organ Repair and Engineering: The Next Step in Tissue Engineering?
9.4.5.1 Engineered Skin
9.4.5.2 Engineered Veins
9.4.5.3 Organ Transplant: A Long-Term Tissue Engineering Opportunity
9.5 The Gene Therapies Submarket 2015-2025
9.5.1 Glybera Approved and Set for Launch in the EU
9.5.2 Gene Therapies Submarket: Revenue Projections 2015-2025
9.5.3 Glybera’s Approval to Drive Submarket Growth from 2014
9.5.4 There Are More Than Five Gene Therapies in Late-Stage Development
9.5.4.1 ProstAtak: Gene Therapy for Prostate Cancer
9.5.4.2 TVEC (Amgen)
9.5.4.3 Generx (Cardium Therapeutics)
9.5.4.4 Spark Therapeutics: Established in 2013 for Ophthalmic Gene Therapy
10. Next-Generation Biologics: Industry Trends 2015-2025
10.1 Next-Generation Biologics: Market Strengths 2014
10.2 Next-Generation Biologics: Market Weaknesses 2014
10.3 The Next-Generation Biologics Market: STEP Analysis 2015-2025
10.3.1 Social Factors: Rising Disease Incidence and Demands for Convenience
10.3.1.1 Rising Incidence in Cardiovascular Disease, Cancer and Diabetes
10.3.1.2 Next-Generation Biologic Development in Emerging Markets
10.3.2 Technological Developments 2015-2025
10.3.3 Economic Pressures 2015-2025
10.3.3.1 High Drug Costs and Healthcare Spending
10.3.3.2 Limited Commercial Potential in Emerging Markets?
10.3.4 Political Issues: Regulatory Developments 2015-2025
10.4 Next-Generation Biologics: Development Trends 2015-2025
10.4.1 Improving Patient Convenience
10.4.2 Sustained Release Biologics: Pegylation and Beyond
10.4.3 Therapeutic Focus for Next-Generation Biologics
10.4.4 Next-Generation Biologics as Personalised Medicine
10.5 Manufacturing Challenges and Opportunities for Next-Generation Biologics
10.5.1 Contract Manufacturers Invest to Follow Development Trends
10.6 Commercialising Next-Generation Biologics
10.6.1 Product Lifecycle Management for First Generation Biologics
10.6.2 Proving Benefit in Next-Generation Products
10.6.3 Biosimilars as a Challenger 2015-2025
10.7 Partnering for Next-Generation Biologic Development
10.7.1 The Role of Big Pharma in the Next-Generation Biologics Market
10.7.2 Most Development Platforms Stem from Small Biotechs
11. Research Interviews from Our Survey
11.1 Dr Edwin Moses, CEO, Ablynx
11.1.1 Ablynx
11.1.2 Ablynx’s Pipeline and Nanobody Technology
11.1.3 On Caplacizumab
11.1.4 Challenges with Current Biological Therapies
11.1.5 The Next-Generation Biologics Market, 2015-2025
11.2 Dr Mike Romanos, CEO, Crescendo Biologics
11.2.1 Crescendo Biologics
11.2.2 The Benefits in Antibody Fragment Therapies
11.2.3 Treatment of Inflammation Indications with Antibody Fragments
11.2.4 Crescendo’s Fragment Pipeline
11.2.5 Development and Production Platforms for Antibody Therapies
11.2.6 Crescendo’s Humabody ADCs and Multi-Specific T-Cell Engagers
11.2.7 CB001, A Topical Biologic
11.2.8 The Next-Generation Biologics Market, 2015-2025
11.3 Sorrento Therapeutics Inc. Team: Dr Gunnar Kaufmann; VP of Research, Dr Kouros Motamed; VP, Strategic Alliances and Clinical Communications and George Uy; EVP and CCO
11.3.1 Sorrento Therapeutics Inc.
11.3.2 Sorrento’s Pipeline
11.3.3 Drivers and Restraints for Next-Generation Biologics
11.3.4 The Next-Generation Biologics Market, 2015-2025
11.4 Dr Fredrik Frejd, CSO, Affibody
11.4.1 Affibody
11.4.2 Challenges with Current Biological Therapies
11.4.2.1 Current Half-Life Extension Technologies
11.4.3 The Benefits of Affibodies Over Current Antibody Therapies
11.4.4 Focus on Inflammation and Autoimmune Diseases
11.4.5 Development of SOBI002
11.4.6 Regulatory Challenges with Novel Biologics
12. Conclusions from the Research and Analysis
12.1 The Next-Generation Biologics Market Will Grow Strongly to 2025
12.1.1 Next-Generation Antibody Development Will Lead the Market
12.2 New Treatment Regimens Will Drive Demand for Next-Generation Biologics
12.3 Challenges Remain in Developing and Commercialising Next-Generation Biologics
【レポート販売概要】
■ タイトル：次世代生物製剤の世界市場：抗体、再生医療、抗体断片/ALP、インスリン、組換え型血液凝固因子、成長ホルモン■ 英文：Next-Generation Biologics: R&D, Industry and Market Forecasts 2015-2025
■ 発行日：2015年5月
■ 調査会社：visiongain
■ 商品コード：VGAIN5052608
■ 調査対象地域：グローバル
- 積層型バスバーの世界市場予測（～2021年）The global laminated busbar market is projected to grow at a CAGR of 5.72% from 2016 to 2021, to reach a market size of USD 955.6 Million by 2021. This growth is attributed to the rise of renewable energy sources in power generation mix and increase in awareness about energy saving and efficiency. The report segments the laminated busbar market based on end-user industry into power electronics, al …
- メタボロミクス（メタボローム解析）の世界市場予測（～2021年）：ガスクロマトグラフィー、HPLC、UPLC、NMR、マススペクトロメトリー、表面ベース質量分析、バイオインフォマティクスThe global metabolomics market is estimated to reach USD 2.39 Billion by 2021, at a CAGR of 14.6% during the forecast period. The growing acceptance of metabolomics for personalized medicine, increasing pharmaceutical and biotech R&D expenditure, and continuous technological advancements are some of the factors driving market growth. New range of enhanced technologies for accuracy and precision in …
- フリップチップの世界市場2018-2022About Flip Chip Flip chip is a type of packaging type, which interconnects chip and package carriers or substrates using a conductive bump. Conductive bumps are placed on the die surface, which is flipped to connect the substrate directly. Technavio’s analysts forecast the Global Flip Chip Market Market to grow at a CAGR of 6.22% during the period 2018-2022. Covered in this report The report cover …
- モバイル端末用NANDフラッシュの世界市場：スマートフォン、タブレットPCAbout NAND Flash NAND flash memory is a non-volatile storage technology which does not require power to retain data. NAND flash development reduces the cost per bit. It maximizes chip capacity as the cells are connected in series connection and occupies lesser space than the ones connected in parallel connection. Thus, NAND flash costs 40 percent cheaper than NOR flash device at the 1 GB levels. N …
- DeRoyal Industries, Inc.：市場シェア分析DeRoyal Industries, Inc. Market Share Analysis Summary GlobalData’s new report, “DeRoyal Industries, Inc. Market Share Analysis” provides in-depth information on DeRoyal Industries, Inc.’s market position in the different medical equipment markets it operates in. The report provides DeRoyal Industries, Inc. market share information in two key market categories – Orthopedic Braces and Supports and …
- 自動車リモートキーレスエントリシステムの世界市場2017-2021About Automotive Remote Keyless Entry System RKE systems were the first form of keyless entry technology introduced in automobiles. An RKE system consists of a key fob that is equipped with a transmitter, which communicates with the vehicle through radio frequency. The receiver installed in the vehicle captures the signal, decodes it, and then instructs the vehicle door to lock or unlock. The key …
- ラボ＆携帯型ラマン装置の世界市場2016-2020About Laboratory and Handheld Raman Instruments Raman instruments are used to identify and break down the chemical composition of physical materials based on the inelastic scattering of monochromatic light obtained when the material or sample is exposed to a light source, usually a laser source. This method is called Raman spectroscopy, and it is used to provide a fingerprint by which molecules ca …
- クリーンインプレースの世界市場2019-2023Global Clean-in-place Market: About this market Technavio’s clean-in-place analysis considers sales from both reuse and single-use products. Our analysis also considers the sales of CIP systems in APAC, Europe, North America, South America, and MEA. In 2018, the reuse product segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as lo …
- 油圧機器の世界市場予測・分析2020-2024Global Hydraulic Equipment Market: About this market Technavio’s hydraulic equipment market analysis considers sales from various type of components such as pump and motor, valve, cylinder, accumulator and filter, and others. Our report also provides a detailed analysis of the market in APAC, Europe, MEA, North America, and South America. In 2019, the mobile application segment had a significant m …
- 糖尿病性ケトアシドーシス（Diabetic Ketoacidosis）：グローバル臨床試験レビュー（2014年上半期）Diabetic Ketoacidosis Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Diabetic Ketoacidosis Global Clinical Trials Review, H1, 2014" provides data on the Diabetic Ketoacidosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Ketoacidosis. It includes an overview of the trial numbers and the …
- 大動脈弁狭窄症：治療薬の治験動向（2014年下半期）Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Aortic Valve Stenosis Global Clinical Trials Review, H2, 2014" provides data on the Aortic Valve Stenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Aortic Valve Stenosis. It includes an overview of the trial numbers and the …
- 金融（BFSI）セキュリティの世界市場2016-2020About BFSI Security Cyber security solutions help organizations maintain data confidentiality by monitoring, detecting, reporting, and countering cyber threats. These solutions can be deployed as on-premises, cloud-based, or hybrid models. Cyber threats are web-based threats that include identity and data theft. These cyber threats disrupt IT systems and hack critical information by using malware …
- 自動光学検査（AOI）システムの世界市場予測（～2024年）“Automated optical inspection system market to exhibit significant growth during 2018–2024”The automated optical inspection (AOI) system market is estimated to grow from USD 444 million by 2018 to USD 1,641.0 million by 2024, at a CAGR of 24.3% during 2018–2024. The key factors driving the growth of the market include growing demand for consumer electronics, increasing need for high-quality electr …
- コンピューター統合生産（CIM)の世界市場2018-2022About Computer Integrated Manufacturing CIM is the integration of manufacturing process, with the help of computers. CIM is a broad concept and includes designing, manufacturing, management, and several other business processes associated with manufacturing. Technavio’s analysts forecast the global computer integrated manufacturing market to grow at a CAGR of 7.02% during the period 2018-2022. Cov …
- 末梢挿入中心静脈カテーテル（PICC）の世界市場2015-2019About peripherally inserted central catheter Peripherally inserted central catheter is a thin, soft, flexible tube used to inject fluids or medications directly into a vein and or to draw blood samples for testing. The device is inserted in a peripheral vein in the arm such as the cephalic vein, basilic vein, or brachial vein. It is then advanced proximally toward the heart through increasingly la …
